ReviewVascular biology (Bristol, England)2026
Trophoblast invasion biology: from normal implantation to accreta spectrum and choriocarcinoma.
Review in Vascular biology (Bristol, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Review
- Locally Advanced Invasive Mole in the Presence of Low Serum β-hCG: A Case Report.International journal of women's health · 2026Article
- Insights into the maternal-fetal interface from spatial multi-omics.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Trophoblast invasion is a finely regulated physiological process that demonstrates controlled cellular migration and vascular remodeling during human pregnancy. During normal implantation, cytotrophoblasts differentiate into extravillous trophoblasts (EVTs), which enter the maternal decidua and remodel spiral arteries, converting them into low-resistance vessels required for fetal nutrition. This balance of invasion and restraint promotes appropriate vascular adaptation at the maternal-fetal interface. Aberrations in this mechanism result in a range of pathological states, from excessive but non-malignant invasion in placenta accreta spectrum (PAS) to uncontrolled, malignant invasion in choriocarcinoma. In PAS, trophoblasts can infiltrate the myometrium due to dysregulated production of matrix metalloproteinases (MMP-2 and MMP-9), integrins, and angiogenic factors (VEGF and HIF-1α). In choriocarcinoma, trophoblastic cells activate PI3K/AKT, Wnt/β-catenin, and Notch signaling, leading to hyperproliferation, immune evasion through PD-L1, and metastatic potential. Despite differences in clinical behavior, many disorders have molecular mediators that link trophoblast invasion to vascular remodeling, angiogenesis, and immunological regulation. Emerging models, including trophoblast organoids, placental explants, and placenta-on-a-chip technologies, offer enhanced platforms to study such pathways at the cellular and molecular levels. This review highlights trophoblast invasion as a model of controlled angiogenic remodeling, providing mechanistic insight into both obstetric pathology and cancer biology. It underscores how studying placental invasion can inform therapeutic strategies targeting abnormal vascular invasion across diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.